This indefinite delivery contract (IDC) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Pfizer Inc. to provide an uninterrupted supply of the drug Bevacizumab for the VA, Department of Defense, Bureau of Prisons, and Indian Health Service. The single-award IDC has a one-year base period from August 2020 to August 2021, with four one-year option periods, for a total potential contract value of $41,351,134.20.
The original procurement, solicitation number 36E79720R0038, sought to establish an unrestricted contract for Bevacizumab, a cancer medication. Offerors had to provide the exact brand name and National Drug Code for the product to be supplied. The annual estimated quantities were 35,277 vials of 100mg and 8,034 vials of 400mg Bevacizumab. The contract enables the VA, DoD, Bureau of Prisons, and Indian Health Service to order Bevacizumab through the VA and DoD Pharmaceutical Prime Vendor Programs to support their respective healthcare initiatives. As a large pharmaceutical manufacturer, Pfizer is well-positioned to fulfill the government's requirements for this critical oncology drug across multiple federal agencies.
Generated 12/22/24, 12:02 AM